HUMA
NASDAQ
$0.66
Humacyte Inc (HUMA)
Humacyte Inc (HUMA) is a groundbreaking biotechnology firm at the forefront of vascular and regenerative medicine, specializing in the development of human acellular vessels (HAVs). These innovative, off-the-shelf products are designed to meet pressing needs in vascular reconstruction and chronic disease management, improving patient outcomes and potentially reducing healthcare expenses. Leveraging its advanced technology platform, Humacyte is strategically positioned to drive innovation in transplantation and tissue engineering, thereby cementing its status as a transformative leader within the rapidly evolving landscape of medical therapies.
This company is also listed under the following ticker: HUMAW.
Website: https://www.humacyte.comSector:
Healthcare
Industry:
Biotechnology
Buy
Target: $2.05 (+212.40%)
Market Cap
$151M
Free Cash Flow Yield
-67.65%
Beta (5Y)
2.46
Price Chart
Valuation
Market Cap$151M
Forward P/E35.84
P/S90.61
P/B15.84
Profitability
Total Revenue (TTM)$2.02M
Gross Profit (TTM)-$82M
EBITDA-$109M
Operating Margin-5704%
EPS-$0.56
Financial Health
Debt-to-Equity308.6%
Free Cash Flow Yield-67.65%
Growth & Risk
Beta (5Y)2.46
Sharpe Ratio-0.58